Brokerages predict that MacroGenics Inc (NASDAQ:MGNX) will announce earnings per share (EPS) of $2.58 for the current quarter, according to Zacks. Five analysts have issued estimates for MacroGenics’ earnings, with the lowest EPS estimate coming in at $2.29 and the highest estimate coming in at $2.99. MacroGenics posted earnings per share of ($1.00) in the same quarter last year, which would suggest a positive year over year growth rate of 358%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that MacroGenics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.94) to ($0.43). For the next year, analysts expect that the business will report earnings of ($5.04) per share, with EPS estimates ranging from ($5.69) to ($4.33). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover MacroGenics.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. During the same period in the previous year, the business earned ($0.97) EPS. The firm’s revenue was down 48.5% compared to the same quarter last year.

Several research analysts recently weighed in on the stock. BidaskClub raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Cowen restated a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. Finally, Raymond James Financial restated a “buy” rating on shares of MacroGenics in a report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $30.10.

In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the sale, the senior vice president now directly owns 40,000 shares in the company, valued at approximately $800,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC raised its holdings in shares of MacroGenics by 6.0% in the second quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock valued at $91,733,000 after purchasing an additional 295,553 shares during the last quarter. BB Biotech AG raised its holdings in shares of MacroGenics by 4.0% in the second quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock valued at $41,150,000 after purchasing an additional 90,112 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of MacroGenics by 2.8% in the second quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock valued at $24,362,000 after purchasing an additional 38,458 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of MacroGenics by 8.9% in the third quarter. Point72 Asset Management L.P. now owns 1,181,317 shares of the biopharmaceutical company’s stock valued at $21,831,000 after purchasing an additional 96,900 shares during the last quarter. Finally, Wasatch Advisors Inc. raised its holdings in shares of MacroGenics by 5,159.3% in the second quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock valued at $18,285,000 after purchasing an additional 1,024,388 shares during the last quarter. Institutional investors own 85.77% of the company’s stock.

MacroGenics (NASDAQ MGNX) traded down $0.19 during trading on Friday, reaching $19.85. 167,400 shares of the company traded hands, compared to its average volume of 179,467. MacroGenics has a twelve month low of $14.36 and a twelve month high of $22.31. The company has a market cap of $737.93, a price-to-earnings ratio of -4.41 and a beta of 2.73.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/macrogenics-inc-mgnx-expected-to-post-earnings-of-2-58-per-share.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.